Condition (MeSH)
Carcinoma, Lobular
ClinicalTrials.gov lists 67 trials for Carcinoma, Lobular or a narrower condition beneath it. Intarcia Therapeutics has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
67 of the 67 trials are tagged with Carcinoma, Lobular itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Lobular trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 1 |
| 2024 | 5 |
| 2023 | 6 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2016 | 1 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 48 months across 37 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Lobular trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 2 |
| Phase 2 | 22 |
| Phase 3 | 6 |
| Not applicable | 12 |
| Observational | 18 |
How many Carcinoma, Lobular trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 13 |
| Active, not recruiting | 9 |
| Completed | 28 |
| Terminated | 5 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Lobular trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Intarcia Therapeutics | 3 |
| Blue Earth Diagnostics | 2 |
| American College of Radiology Imaging Network | 1 |
Which drugs are being tested for Carcinoma, Lobular? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Atamestane | 3 |
| Toremifene | 3 |
| Cytoxan | 3 |
| FULVESTRANT | 2 |
| TRASTUZUMAB | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Letrozol (Femara, Novartis) | 6 |
| Endocrine Therapy | 5 |
| or carboplatin | 4 |
| Radiation Therapy | 4 |
| Adjuvant Therapy | 3 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Lobular trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil count decreased | 37 | 2 |
| Fatigue | 13 | 3 |
| Breast infection | 12 | 1 |
| Skin infection | 12 | 2 |
| Chest wall pain | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Lobular? (278)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Breast Cancer Recurrence after Cryoablation in Patients Who Are Poor Surgical Candidates or Who Refuse Surgery. | Journal of vascular and interventional radiology : JVIR | 2025 | Yes |
| Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes. | Breast cancer research and treatment | 2025 | Yes |
| Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance. | Asia-Pacific journal of clinical oncology | 2025 | Yes |
| Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study. | Breast cancer research : BCR | 2025 | Yes |
| Triple-negative lobular breast cancer: focus on pathology and clinical challenges. | Human pathology | 2025 | Yes |
Showing 5 of 278 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.